Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | TSHR | P16473 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CCR3 | P51677 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | MC4R | P32245 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24685832 | 0.91 | CCR3 (0.61) | GAAOPRL1POLBKMT2ATSHR | |
| SCHEMBL3252230 | 0.90 | OPRL1 (0.65) | GAAOPRL1POLBKMT2ATSHR | |
| SCHEMBL1991427 | 0.90 | GAA (0.51) | GAAOPRL1POLBKMT2ATSHR | |
| SCHEMBL18084501 | 0.90 | GAA (0.51) | GAAOPRL1POLBKMT2ATSHR | |
| SCHEMBL27550808 | 0.88 | OPRL1 (0.63) | GAAOPRL1POLBKMT2ATSHR | |
| Hydrochloric Acid SCHEMBL6160179 | 0.88 | POLB (0.66) | GAAOPRL1POLBKMT2ATSHR | |
| SCHEMBL16884628 | 0.86 | GAA (0.51) | GAAOPRL1POLBKMT2ATSHR | |
| SCHEMBL31230950 | 0.86 | GAA (0.71) | GAAOPRL1POLBKMT2ATSHR | |
| SCHEMBL15763337 | 0.83 | OPRM1 (0.51) | GAAOPRL1OPRM1 | |
| SCHEMBL4817148 | 0.81 | CYP3A4 (0.56) | GAAOPRL1POLBKMT2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230227428-A1 | AMIDO COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2023-07-20 | — | — | US | disclosed |
| US-20230227428-A1 | AMIDO COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2023-07-20 | — | — | US | disclosed |
| US-20230227428-A1 | AMIDO COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2023-07-20 | — | — | US | disclosed |
| WO-2021253098-A1 | AMIDO COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2021-12-23 | — | — | WO | disclosed |
| WO-2021253098-A1 | AMIDO COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2021-12-23 | — | — | WO | disclosed |
| US-20180169099-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2018-06-21 | — | — | US | disclosed |
| US-9717730-B2 | Combinations of AKT inhibitor compounds and chemotherapeutic agents, and methods of use | GENENTECH, INC. (US) | 2017-08-01 | — | — | US | disclosed |
| US-20170157124-A1 | COMBINATIONS OF AKT INHIBITOR COMPOUNDS AND CHEMOTHERAPEUTIC AGENTS, AND METHODS OF USE | GENENTECH, INC. (US) | 2017-06-08 | — | — | US | disclosed |
| US-9610289-B2 | Combinations of AKT inhibitor compounds and erlotinib, and methods of use | GENENTECH, INC. (US) | 2017-04-04 | — | — | US | disclosed |
| US-20160235754-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2016-08-18 | — | — | US | disclosed |
| US-20130065908-A1 | DIHYDROFURO PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2013-03-14 | — | — | US | disclosed |
| US-20120329808-A1 | DIHYDROTHIENO PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2012-12-27 | — | — | US | disclosed |
| US-8329701-B2 | Dihydrofuro pyrimidines as AKT protein kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2012-12-11 | — | — | US | disclosed |
| US-20120232055-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | GENENTECH, INC. (US) | 2012-09-13 | — | — | US | disclosed |
| US-8063050-B2 | Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-20110269773-A1 | DIHYDROFURO PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA, INC. | 2011-11-03 | — | — | US | disclosed |
| US-20110245230-A1 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2011-10-06 | — | — | US | disclosed |
| US-8003651-B2 | Pyrimidyl cyclopentanes as AKT protein kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2011-08-23 | — | — | US | disclosed |
| US-20080058327-A1 | 4-piperazinyl-5H-6,7-dihydrocyclopenta(d)pyrimidines; Hyperproliferative diseases such as cancer | GENENTECH, INC. | 2008-03-06 | — | — | US | disclosed |
| US-20080051399-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2008-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170157124-A1 | COMBINATIONS OF AKT INHIBITOR COMPOUNDS AND CHEMOTHERAPEUTIC AGENTS, AND METHODS OF USE | AKT1, AKT2, MTOR | GAA 2951/4885OPRL1 3600/4885POLB 1311/4885 |
| US-20080058327-A1 | 4-piperazinyl-5H-6,7-dihydrocyclopenta(d)pyrimidines; Hyperproliferative diseases such as cancer | PIK3CA, DPYD, CDK2 | GAA 1922/4885OPRL1 3605/4885POLB 190/4885 |
| US-20160235754-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT3 | GAA 2389/4885OPRL1 3780/4885POLB 672/4885 |
| US-20130065908-A1 | DIHYDROFURO PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS | DPYD, DTYMK, PIK3CA | GAA 1923/4885OPRL1 4536/4885POLB 385/4885 |
| US-20230227428-A1 | AMIDO COMPOUNDS | RIPK1, RIPK3, MLKL | GAA 2270/4885OPRL1 1349/4885POLB 3470/4885 |
| US-20080051399-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT1S1 | GAA 2430/4885OPRL1 3551/4885POLB 613/4885 |
| US-20110269773-A1 | DIHYDROFURO PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS | DPYD, PIK3CA, DTYMK | GAA 1939/4885OPRL1 4534/4885POLB 367/4885 |
| US-20180169099-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT1S1 | GAA 2430/4885OPRL1 3551/4885POLB 613/4885 |
| US-20120329808-A1 | DIHYDROTHIENO PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS | DTYMK, TK1, PIK3CA | GAA 2535/4885OPRL1 4309/4885POLB 429/4885 |
| US-20120232055-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT1S1 | GAA 2430/4885OPRL1 3551/4885POLB 613/4885 |
| US-20110245230-A1 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | TK1, PIK3CA, AKT1 | GAA 1749/4885OPRL1 3499/4885POLB 751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.